Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Pediatric Hematology/Oncology
•
Medical Oncology
•
Hematology
Would you consider bone marrow transplant in a pediatric patient with recurrent HLH with no identified exogenous trigger or HLH-associated mutation?
Related Questions
Given the data from SWOG 1826 suggesting that Nivo-AVD is likely the preferred regimen for advanced Hodgkin lymphoma patients, are there scenarios where alternative regimens may still be preferred?
What are your top takeaways in Classical Hematology from ASH 2024?
What is the optimal timing for PET/CT to assess disease and treatment response with nivo + AVD?
How would you treat suspected secondary HLH in patients whom etoposide is contraindicated?
How do different inflammatory markers like CRP and ferritin contribute differently, if at all, to the monitoring of CART neurotoxicity?
Is there any indication for IVIG in immunocompromised patients with only decreased IgM and/or IgA levels?
What is your approach to screening a cancer survivor for iron overload, and what is your treatment of choice?
What are your top takeaways in Hematologic Malignancies from ASH 2024?
How do you manage patients desiring home hospice but with severe thrombocytopenia and/or anemia due to advanced malignancy?
How do you counsel sickle cell patients on the use of G-CSF to treat neutropenia from other causes, like malignancy?
